In-hospital use of ACE inhibitors/angiotensin receptor blockers associates with COVID-19 outcomes in African American patients
Journal of Clinical Investigation Oct 07, 2021
Li S, Sarangarajan R, Jun T, et al. - A significant reduction in in-hospital mortality was observed among COVID-19–positive African American patients in correlation with in-hospital use of angiotensin receptor blockers.
Between February 24 and May 31, 2020, a total of 6,218 patients were identified who were admitted with COVID-19 in Mount Sinai hospitals in New York City; 1,138 of these patients (18.3%) received angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACE-I/ARB).
A multivariate logistic regression model revealed independent correlation of ACE-I/ARB use with a lowered risk of in-hospital mortality in the entire population.
The African American population had improved mortality in correlation with in-hospital use of ACE-I/ARB, but not with outpatient use.
Separate analysis of each medication class revealed significant correlation of ARB in-hospital use with reduced in-hospital mortality in the African American population, whereas there appeared no influence of ACE-I use on mortality in any population.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries